- About Us
- Services & Solutions
- Nucleic Acid Vaccines
- Viral Vector Vaccines
Offering End-to-End Solutions
Suzhou, China, January 25, 2024 – WuXi Vaccines, a world-leading vaccine Contract Development and Manufacturing Organization (CDMO), and Delonix Bioworks Ltd. (“Delonix”), a world-leading biotech company dedicated to the design and engineering of microbes for medicines, announced an agreement to accelerate the development and manufacturing of Delonix’s innovative bacterial vaccines.
Under the agreement, WuXi Vaccines’ extensive technical expertise, deep regulatory experience, world-class quality system, advanced CMC development capabilities, and robust GMP manufacturing capacity will enable Delonix to speed its vaccine pipeline towards Investigational New Drug (IND) application and commercialization globally.
Mr. Jian Dong, CEO of WuXi Vaccines, commented, “We’re very pleased to reach the agreement with Delonix to expedite the development and manufacture of their innovative bacterial vaccines. Adhering to the highest quality standards and providing end-to-end services for clients with our integrated platforms, we continue our commitment to enabling the advancement of vaccine accessibility and affordability in the global health community.”
Dr. Qiubin Lin, Founder and CEO of Delonix, commented, “We’re delighted to partner with WuXi Vaccines and take advantage of their leading vaccine CDMO platform. Their integrated R&D and manufacturing solutions will further facilitate Delonix’s unique know-how and technologies, and ultimately translate our advanced vaccine research results into market-ready products.”
Delonix Bioworks is a leading synthetic biology company specializing in innovative vaccine development. It has advanced gene editing and modification capabilities for over ten pathogens, making it a global leader in genetically engineered vaccine development. The company has significant expertise in engineering key vaccine components, such as polysaccharides, detoxified LPS, and bacterial outer membrane vesicles (OMVs).
The company has launched two proprietary synthetic vaccine platforms: ProBVax, an engineered whole-cell vaccine platform, and BioDVax, an engineered subunit vaccine platform. With these two innovative platforms, Delonix has successfully developed a range of world-class innovative vaccine pipelines, several of which are expected to reach the clinical stage within the next two years.
Since 2021, Delonix has received recognition from various organizations, including the Boehringer Ingelheim Innovation Prize (Champion) and the Venture 50 “New Seed List Top 50”. For more information, please visit: https://delonixbio.com.
About WuXi Vaccines
WuXi Vaccines is a leading contract development and manufacturing organization (CDMO) that focuses on vaccine development and manufacturing. It provides world-class, integrated development and manufacturing platforms to expedite partners’ vaccines to the clinical stage and the market, regardless of the vaccine modality (i.e., recombinant protein, viral, viral vectored, VLP, OMV, nucleic acid, conjugated vaccines). With its technical expertise, broad regulatory knowledge, premium quality system, advanced CMC development capabilities, multiple production platforms (cell culture, viral, microbial, polysaccharide and protein conjugation), and extensive GMP manufacturing capacities, WuXi Vaccines provides an end-to-end service – from vaccine discovery and development to large-scale commercial production and distribution. The company can enable global clients to deliver critical vaccines anywhere in the world, making it an essential partner in protecting public health. For more information about WuXi Vaccines, please visit: https://wuxivaccines.com.